Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UnipharDUB:UPR +0.68%82 Debt-to-EBITDA is 3.68 as of Dec. 2025, which is 5% above its 10-year median of 3.50. GuruFocus rates DUB:UPR with a GF Score™ of 82/100 and a GF Value™ of €3.65 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 90 Medical Distribution companies, Uniphar ranks worse than 70% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Uniphar's Debt-to-EBITDA or its related term are showing as below:
DUB:UPR'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.74 Med: 3.5 Max: 7.8
Current: 4.28
During the past 10 years, the highest Debt-to-EBITDA Ratio of Uniphar was 7.80. The lowest was 2.74. And the median was 3.50.
DUB:UPR's Debt-to-EBITDA is ranked worse than 70% of 90
companies
in the Medical Distribution industry
Industry Median: 2.45
vs DUB:UPR: 4.28
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Uniphar Debt-to-EBITDA Related Terms
Uniphar Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Uniphar's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DUB:UPR vs MCK, CAH, COR: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, Uniphar's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Uniphar Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Uniphar's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Uniphar's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Uniphar (DUB:UPR) has a Debt-to-EBITDA of 3.68 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Uniphar. This is near median its historical median of 3.50. Over the past decade, Uniphar's Debt-to-EBITDA has ranged from 2.74 to 7.80. According to the industry distribution chart, Uniphar ranks #63 out of 90 companies in the Medical Distribution industry, placing it in the top 70%.
Is Uniphar's Debt-to-EBITDA too high?
Uniphar's current Debt-to-EBITDA of 3.68 is near median its 10-year median of 3.50. Over the past 10 years, this metric has ranged from a low of 2.74 to a high of 7.80. The Medical Distribution industry median Debt-to-EBITDA is 2.45. Uniphar's value of 3.68 is 50.2% above this industry median. Based on the distribution chart, Uniphar ranks #63 out of 90 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Uniphar has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Uniphar's Debt-to-EBITDA compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Uniphar ranks #63 out of 90 companies for Debt-to-EBITDA. This places Uniphar in the lower half of its industry. The industry median Debt-to-EBITDA is 2.45. Uniphar's value of 3.68 is 50.2% above this benchmark. Historically, Uniphar's own Debt-to-EBITDA has ranged from 2.74 to 7.80 over the past decade. While the company's 10-year median is 3.50 vs. the industry median of 2.45, Uniphar has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.45, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Uniphar's current Debt-to-EBITDA of 3.68 is 50.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Uniphar. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Uniphar's current Debt-to-EBITDA is 3.68, which is near median its own 10-year median of 3.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uniphar stock overvalued right now?
Based on GuruFocus' analysis, Uniphar (DUB:UPR) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.65, compared to a current price of €4.47 — trading 22.5% above its estimated fair value. The current Debt-to-EBITDA is 3.68, which is near median its 10-year median of 3.50 and 50.2% above the Medical Distribution industry median of 2.45. Uniphar's overall GF Score™ is 82/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Uniphar (DUB:UPR), the current Debt-to-EBITDA is 3.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Uniphar (DUB:UPR) Overvalued in 2026?
Based on GuruFocus' analysis, Uniphar stock appears to be overvalued.
The current stock price of €4.47 is trading 22.5% above its estimated GF Value™ of €3.65.
GuruFocus considers Uniphar to be Modestly Overvalued.
Key valuation signals for DUB:UPR:
Debt-to-EBITDA: 3.68 (near median its 10-year median of 3.50)
GF Value™: €3.65 vs. price of €4.47 (22.5% above fair value)
Industry Position: 50.2% above the Medical Distribution median (#63 of 90)
No single metric tells the full story. See the DUB:UPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies.
82GF Score
Get the complete analysis for DUB:UPR
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DUB:UPR has been successfully added to your 
